Altimmune (ALT) Net Income towards Common Stockholders (2010 - 2026)

Altimmune (ALT) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$22.6 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 15.26% year-over-year to -$22.6 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 113.44% increase from a year earlier, with the FY2025 full-year figure at $15.1 million, up 120.13% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$22.6 million, down from $75.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ALT reached as high as $75.9 million in Q4 2025 and fell as low as -$31.6 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$15.6 million across 5 years, with a median of -$20.7 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders sank 228.09% in 2023 and surged 427.24% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$9.6 million in 2022, then sank by 228.09% to -$31.6 million in 2023, then increased by 26.74% to -$23.2 million in 2024, then jumped by 427.24% to $75.9 million in 2025, then tumbled by 129.74% to -$22.6 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$22.6 million in Q1 2026, $75.9 million in Q4 2025, and -$19.0 million in Q3 2025.